Log in

NYSEAMERICAN:PTNPalatin Technologies Stock Price, Forecast & News

$0.45
+0.03 (+7.14 %)
(As of 04/10/2020 02:53 AM ET)
Add
Compare
Today's Range
$0.42
Now: $0.45
$0.45
50-Day Range
$0.87
MA: $0.93
$1.06
52-Week Range
$0.36
Now: $0.45
$1.78
Volume1.47 million shs
Average Volume1.52 million shs
Market Capitalization$103.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Read More
Palatin Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees19
Market Cap$103.16 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.


Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Palatin Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Palatin Technologies.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings results on Tuesday, February, 11th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to analyst estimates of $4.48 million. During the same period in the previous year, the firm earned ($0.02) EPS. View Palatin Technologies' earnings history.

What price target have analysts set for PTN?

3 brokers have issued 12 month target prices for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' share price to reach $3.67 in the next year. This suggests a possible upside of 714.8% from the stock's current price. View analysts' price targets for Palatin Technologies.

Has Palatin Technologies been receiving favorable news coverage?

News articles about PTN stock have trended very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Palatin Technologies earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPalatin Technologies.

Who are some of Palatin Technologies' key competitors?

What other stocks do shareholders of Palatin Technologies own?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)
  • Burns McClellan, VP of Investor Relations

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.45.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $103.16 million. Palatin Technologies employs 19 workers across the globe. View additional information about Palatin Technologies.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is http://www.palatin.com/.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: 52-Week High/Low

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel